The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B, Wentzel H, Hill A, Sadeghi A, Freeman J, Salmanzadeh S, Esmaeilian H, Mobarak M, Tabibi R, Jafari Kashi AH, Lotfi Z, Talebzadeh SM, Wickramatillake A, Momtazan M, Hajizadeh Farsani M, Marjani S, Mobarak S.
Eslami G, et al. Among authors: marjani s.
J Antimicrob Chemother. 2020 Nov 1;75(11):3366-3372. doi: 10.1093/jac/dkaa331.
J Antimicrob Chemother. 2020.
PMID: 32812051
Free PMC article.
Clinical Trial.